Details for Patent: 12,161,628

« Back to Dashboard

Which drugs does patent 12,161,628 protect, and when does it expire?

Patent 12,161,628 protects XTANDI and is included in two NDAs.

This patent has one patent family member in one country.

Summary for Patent: 12,161,628

Title:	Combination therapy
Abstract:	This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer.
Inventor(s):	Jacqueline GIBBONS, Joyce MORDENTI, Michiel DE VRIES, Walter KRAUWINKEL, Taoufik Ouatas
Assignee:	Astellas Pharma Inc , Medivation Prostate Therapeutics LLC
Application Number:	US17/959,350
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,161,628
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,161,628

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes						TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes						TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes						TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes						TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE

International Family Members for US Patent 12,161,628

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2017027665